Written by 
Drug discovery has always been a time-consuming process. On an average, it takes 10-15 years and capital investments worth USD 4-10 billion to commercially launch a drug.
The global quantum computing market size is estimated to grow from USD 0.39 billion in 2024 to USD 1.63 billion by 2035, representing a CAGR of 13.86% during the forecast period till 2035.
Company Competitiveness of Quantum Computing Software Providers
In this analysis, we have presented a detailed competitiveness analysis of the quantum computing software providers based in North America, Europe, Asia-Pacific and Rest of the World. The companies considered in this analysis have been scored on various relevant parameters, such as company strength (in terms of number of years since it was established), portfolio strength (this parameter evaluates a company’s portfolio strength based on the type of drug discovery service(s) offered, types of molecule(s) support, compatible computational approaches and end user(s)), portfolio diversity (this parameter evaluates a company’s portfolio diversity based on the type of business capabilities). The primary purpose of this analysis was to develop a better understanding of the overall potential and capabilities of companies involved in this domain. In addition, it provides a reliable framework for geographical benchmarking of the capabilities of industry stakeholders.
It involves various processes such as target identification, validation, hit generation, hit to lead and lead optimization. The term quantum computing refers to the technology that uses laws of quantum mechanics to solve large and complex problems in a short span as compared to the computer aided drug discovery. During our research, we were able to identify the presence of about 50 software providers that are engaged in offering services across drug discovery.
The following approach was adopted to compare the capabilities of various companies that are engaged in this domain:
- As a starting point, we collated information on the aforementioned parameters for 49 companies that presently claim to offer services for quantum computing in drug discovery, and thus, were considered in this analysis.
- These companies were then segregated on the basis of their geographical location into three peer groups, namely North America, Europe, and Asia Pacific and Rest of the World.
- We then calculated the scores for company strength (Px), portfolio strength (Py) and portfolio diversity (Pz), for various quantum computing software providers.
- Based on these scores, competitiveness of software providers, across different regions, was presented in the form of three-dimensional bubble charts, with company strength on abscissa and portfolio strength on the Further, the size of the bubble was varied based on the portfolio diversity.
According to our proprietary scoring criteria, in Europe Accenture has emerged to be relatively superior, in terms of company strength. The firm offer platform / software, quantum as a service and drug discovery service as its business capabilities.
Further, in terms of portfolio strength, Hafnium Labs has emerged as the leading player offering Q-props platform. The platform has capability to offer services for different types of drug discovery services including target discovery / identification, target validation / selection, hit generation / identification / discovery, hit to lead / hit expansion / target to lead / lead identification / select lead series and lead optimization.
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/quantum-computing-in-drug-discovery.html
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.
The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.
Contact:
Roots Analysis
+1 (415) 800 3415